Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1998-08-18
2003-02-11
LeGuyader, John L. (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S325000, C435S375000, C435S455000, C536S023100, C536S024500
Reexamination Certificate
active
06518017
ABSTRACT:
FIELD OF THE INVENTION
This invention relates generally to the fields of organic chemistry and biological assays. More specifically, the invention relates to methods and compositions for determining optimal antisense sequences, and optimized libraries of oligonucleotide analogs.
BACKGROUND OF THE INVENTION
Antisense technology is based on the finding that DNA and/or RNA transcription or translation can be modulated using an oligonucleotide which binds to the target nucleic acid. By exploiting the Watson-Crick base pairing, one can design antisense molecules having a very high degree of specificity for the target nucleic acid. Oligonucleotides having only standard (“natural”) bases and backbones must in general contain at least 17 bases in order to bind with sufficient energy to effectively down-regulate gene expression by activating RNase H.
However, even given DNA or RNA of known sequence, it is still difficult to design an optimally effective antisense molecule. This is because nucleic acids are subject to the formation of a variety of secondary and tertiary structures in vivo, and are frequently coiled, supercoiled, folded, and/or obscured by proteins. Some portions of the target sequence are much more susceptible to binding and hybridization by antisense molecules, while other portions of the target sequence are essentially hidden or unavailable. Typically, 20 to 50 oligonucleotides are tested to find one or more active antisense sites per gene.
Standard methods for selecting antisense sites within pre-mRNA or mRNA sequences are insufficient for the rapid, high-throughput application of antisense to large scale target validation programs. Oligonucleotides must be “custom-synthesized” for each target site within each target gene. A standing library of millions or billions of conventional oligonucleotides would be required to successfully target each of the approximately 100,000 human genes. An ordered library of millions of antisense oligonucleotides is beyond the chemical, physical, and organizational tools currently available.
SUMMARY OF THE INVENTION
A new method for preparing and testing antisense and ribozyme sequences has now been invented.
One aspect of the invention is a composition comprising two oligonucleotide analogs, each having a binding domain and a coupling moiety, wherein the binding domains are capable of hybridizing to a target polynucleotide, and the coupling moieties are capable of coupling to each other in the absence of a target molecule.
Another aspect of the invention is a compound of the formula R
1
—L
1
—X—A—Y—L
2
—R
2
, wherein R
1
is an oligonucleotide, or an oligonucleotide analog, capable of binding to
RNA; R2
is an oligonucleotide, or an oligonucleotide analog, capable of binding to RNA; L
1
and L
2
are each independently a linking moiety or a bond; X and Y are each independently a coupling moiety; and A comprises a link selected from the group consisting of a covalent bond, a metal ion, and a non-covalent bond, wherein said compound is capable of activating a nuclease or catalyzing cleavage when bound to a target polynucleotide.
Another aspect of the invention is a method for cleaving a target polynucleotide, comprising providing a target RNA molecule; contacting the target RNA molecule with a first oligonucleotide analog, comprising a first binding domain capable of binding a first region of a target polynucleotide, and a first coupling moiety capable of binding to a second coupling moiety, and a second oligonucleotide analog, comprising a second binding domain capable of binding a second region of said target polynucleotide, and a second coupling moiety capable of binding to said first coupling moiety, wherein said first and second binding domains are capable of binding simultaneously to said target RNA molecule; and incubating said target RNA molecule, first analog and second analog in the presence of an RNase capable of cleaving the RNA target.
Another aspect of the invention is a method for cleaving a target RNA molecule, comprising providing a target RNA molecule; contacting the target RNA molecule with a first oligonucleotide analog, comprising a first binding domain capable of binding a first region of a target polynucleotide, and a first coupling moiety capable of binding to a second coupling moiety, and a second oligonucleotide analog, comprising a second binding domain capable of binding a second region of said target polynucleotide, and a second coupling moiety capable of binding to said first coupling moiety, wherein said first and second binding domains are capable of binding simultaneously to said target RNA molecule; and incubating said target RNA molecule, first analog and second analog in the presence of an RNase capable of cleaving the RNA target.
Another aspect of the invention is an antisense library, comprising a set of first oligonucleotide analogs, each first analog comprising a first coupling moiety and a first binding domain, said first binding domain comprising a first backbone and a plurality of first bases capable of base-pairing with a target nucleic acid; and a set of second oligonucleotide analogs, each second analog comprising a second coupling moiety capable of coupling specifically to said first coupling moiety, and a second binding domain, said second binding domain comprising a second backbone and a plurality of second bases capable of base-pairing with a target nucleic acid; wherein an antisense analog consisting of a first analog coupled to a second analog is capable of binding to a target nucleic acid and serving as a nuclease substrate.
Another aspect of the invention is a library of antisense precursor compounds, a plurality of compounds of formula 2 (R
1
—L
1
—X) and a plurality of compounds of formula 3 (Y—L
2
—R
2
), wherein R
1
and R
2
are each independently an oligonucleotide or an oligonucleotide analog, capable of binding to mRNA; L
1
and L
2
are each independently a linking moiety or a bond; X and Y are each independently a coupling moiety; and wherein said compounds of formula 2 and formula 3 can be coupled to form a compound capable of recruiting or activating a nuclease when bound to a target polynucleotide.
Another aspect of the invention is a library of ribozyme precursor compounds, comprising a plurality of compounds of formula 4 (GG-R
1
-CUGAUGA-L
1
-X) and a plurality of compounds of formula 5 (Y-L
2
-GAA-R
2
), wherein R
1
and R
2
are each independently an oligonucleotide or an oligonucleotide analog, capable of binding to RNA; L
1
and L
2
are each independently a linking moiety or a bond; X and Y are each independently a coupling moiety; and wherein said compounds of formula 4 and formula 5 can be coupled to form a ribozyme.
Another aspect of the invention is a method for determining an optimal antisense site for a given mRNA, comprising: selecting a plurality of first oligonucleotide analogs, said first analogs comprising a first coupling moiety and a first binding domain which is complementary to said mRNA; selecting a second oligonucleotide analog for each first oligonucleotide analog, said second analog comprising a second coupling moiety capable of binding said first coupling moiety, and a second binding domain which is complementary to said RNA at a position proximal to the site to which said first binding domain is complementary; coupling said first coupling moieties and said second moieties to provide a plurality of antisense probes; contacting said mRNA with said antisense probes in the presence of an RNase to form a cleavage product; and determining which antisense probe corresponds to said cleavage product.
Another aspect of the invention is a method for determining an optimal ribozyme cleavage site for a given target RNA, comprising: selecting a plurality of first oligonucleotide analogs, said first analogs comprising a first coupling moiety and a first binding domain which is complementary to said target RNA; selecting a second oligonucleotide analog for each first oligonucleotide analog, said second analog comprising a second coupling moiety capable of bi
Arnold Lyle J.
Brown Bob D.
Riley Timothy A.
Knobbe Martens Olson & Bear LLP
LeGuyader John L.
Oasis Biosciences Incorporated
Schmidt Mary M
LandOfFree
Combinatorial antisense library does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinatorial antisense library, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinatorial antisense library will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3179867